English
Home > Products > Lacosamide advance intermediate

China Lacosamide advance intermediate Factory

"Sincerity, Innovation, Rigorousness, and Efficiency" is the persistent conception of our firm for the long-term to create jointly with consumers for mutual reciprocity and mutual reward for Lacosamide advance intermediate,CAS NO 86123-95-7,86123-95-7,Lacosamide intermediate,D-Serine, N-[(1,1-dimethylethoxy), Being a young escalating company, we might not the top, but we're trying our best to generally be your superior partner.
Lacosamide advance intermediate, We are sincerely looking forward to cooperate with customers all over the world. We believe we can satisfy you with our high-quality goods and perfect service . We also warmly welcome customers to visit our company and purchase our solutions.

Related Products

Hot Products

  • Citicoline sodium

    Citicoline sodium

    Product Name:Citicoline sodium
    Molecular Formula:C14H27N4NaO11P2
    Molecular Weight;512.32
    CAS Registry Number;33818-15-4
  • 1-Methyl-aminomethyl naphthalene

    1-Methyl-aminomethyl naphthalene

    Product Name:1-Methyl-aminomethyl naphthalene
    Molecular Formula:C12H13N
    Molecular Weight:171.24
    CAS Registry Number:14489-75-9
  • (S)-3-(4-(2-Chloro-5-Iodobenzyl)Phenoxy)-Tetrahydrofuran

    (S)-3-(4-(2-Chloro-5-Iodobenzyl)Phenoxy)-Tetrahydrofuran

    Product Name:(S)-3-(4-(2-Chloro-5-Iodobenzyl)Phenoxy)-Tetrahydrofuran
    CAS NO:915095-94-2
    Molecular Formula:C17H16ClIO2
    Formula Weight:414.67
    Usage:Empagliflozin Intermediates​
  • N-Boc-4-piperidinemethanol

    N-Boc-4-piperidinemethanol

    Product Name:N-Boc-4-piperidinemethanol
    Molecular Formula:C11H21NO3
    Molecular Weight:215.29
    CAS Registry Number:123855-51-6
  • Ellagic acid

    Ellagic acid

    Product Name:Ellagic acid
    Molecular Formula:C14H6O8
    Molecular Weight;302.19
    CAS Registry Number;476-66-4
  • 4,4'-(4,4'-Isopropylidenediphenyl-1,1'-diyldioxy)dianiline

    4,4'-(4,4'-Isopropylidenediphenyl-1,1'-diyldioxy)dianiline

    Product Name:4,4'-(4,4'-Isopropylidenediphenyl-1,1'-diyldioxy)dianiline
    Molecular Formula:C27H26N2O2
    Molecular Weight:410.51
    CAS Registry Number:13080-86-9
  • Related Blog
  • Reviews

  • Everything You Need To Know About Active Pharmaceutical Ingredients (API In Pharma)

    Sandoo, as a professional API manufactruer in China, we produces a wide range of active pharmaceutical ingredients which can be used in the production of medicines in different applications.

  • Caffeine CAS No.58-08-2

    Caffeine (CAS No.58-08-2) is a xanthine alkaloid compound, a central nervous stimulant that temporarily drives away drowsiness and restores energy, and is used clinically to treat neurosis and coma recovery. Caffeinated coffee, tea, soft drinks and energy drinks are very popular, so caffeine is also the most commonly used psychotropic drug in the world.

  • What is an Active Pharmaceutical Ingredient (API in Pharma)?

    Sandoo Pharmaceutical is a professional active pharmaceutical intermediate manufacturer, producing high quality APIs. Sandoo Pharmaceutical provides a wide range of active pharmaceutical intermediates.

  • Why API manufacturing companies almostly in China?

    In the chemical API industry, developed countries such as the United States and Europe occupy a dominant position in the field of patented APIs with high added value by virtue of their advantages in research and development, production technology, and intellectual property protection...

  • How to find the best China API manufacturer?

    Active pharmaceutical ingredients or APIs can be defined as the chemicals used to manufacture pharmaceutical drugs. The active ingredient (AI) is the substance or substances that are biologically active within the drug and is the specific component responsible for the desired effect it has on the individual taking it.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept